PIII Net Income From Continuing Ops from 2010 to 2026

PIII Stock  USD 2.02  0.50  32.89%   
P3 Health's Net Loss is decreasing with slightly volatile movements from year to year. Net Loss is predicted to flatten to about -293.3 M. For the period between 2010 and 2026, P3 Health, Net Loss quarterly trend regression had median of (49,774,014) and r-value of (0.46). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-279.3 M
Current Value
-293.3 M
Quarterly Volatility
500 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check P3 Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among P3 Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 103.9 M, Interest Expense of 26.8 M or Selling General Administrative of 93.6 M, as well as many indicators such as Price To Sales Ratio of 0.0238, Dividend Yield of 0.0 or PTB Ratio of 0.37. PIII financial statements analysis is a perfect complement when working with P3 Health Valuation or Volatility modules.
  
Build AI portfolio with PIII Stock
Check out the analysis of P3 Health Correlation against competitors.
The Net Income From Continuing Ops trend for P3 Health Partners offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether P3 Health is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest P3 Health's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of P3 Health Partners over the last few years. It is P3 Health's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in P3 Health's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

PIII Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(305,414,998)
Coefficient Of Variation(163.71)
Mean Deviation336,645,060
Median(49,774,014)
Standard Deviation499,989,280
Sample Variance249989.3T
Range1.5B
R-Value(0.46)
Mean Square Error209607.5T
R-Squared0.21
Significance0.06
Slope(45,796,756)
Total Sum of Squares3999828.5T

PIII Net Income From Continuing Ops History

2026-293.3 M
2025-279.3 M
2024-310.4 M
2023-649.7 M
2021-1.6 B
2020-45.4 M
2019-42.9 M

About P3 Health Financial Statements

Investors use fundamental indicators, such as P3 Health's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although P3 Health's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss-279.3 M-293.3 M

Currently Active Assets on Macroaxis

When determining whether P3 Health Partners is a strong investment it is important to analyze P3 Health's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact P3 Health's future performance. For an informed investment choice regarding PIII Stock, refer to the following important reports:
Check out the analysis of P3 Health Correlation against competitors.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is there potential for Health Care Equipment & Supplies market expansion? Will PIII introduce new products? Factors like these will boost the valuation of P3 Health. Anticipated expansion of PIII directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about P3 Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(57.16)
Revenue Per Share
442.863
Quarterly Revenue Growth
(0.05)
Return On Assets
(0.21)
Return On Equity
(2.03)
P3 Health Partners's market price often diverges from its book value, the accounting figure shown on PIII's balance sheet. Smart investors calculate P3 Health's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since P3 Health's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between P3 Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding P3 Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, P3 Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.